Mesoblast (NASDAQ:MESO) Shares Gap Up – What’s Next?

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $14.58, but opened at $15.16. Mesoblast shares last traded at $15.38, with a volume of 148,913 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mesoblast in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Mesoblast currently has a consensus rating of “Moderate Buy”.

Mesoblast Trading Up 1.1%

The stock has a fifty day moving average of $17.42 and a 200-day moving average of $16.86. The company has a market cap of $2.05 billion, a PE ratio of -18.01 and a beta of 2.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.77 and a current ratio of 1.58.

Mesoblast (NASDAQ:MESO) last released its earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $25.67 million during the quarter. Sell-side analysts anticipate that Mesoblast Limited will post -0.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Mesoblast

A number of institutional investors have recently modified their holdings of MESO. Mirae Asset Global Investments Co. Ltd. grew its stake in Mesoblast by 30.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock worth $43,000 after purchasing an additional 558 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of Mesoblast by 5.4% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 14,047 shares of the company’s stock worth $226,000 after buying an additional 716 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Mesoblast by 55.6% during the third quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock valued at $46,000 after buying an additional 1,012 shares during the period. Summit X LLC increased its stake in shares of Mesoblast by 0.6% during the second quarter. Summit X LLC now owns 199,295 shares of the company’s stock valued at $2,170,000 after buying an additional 1,132 shares during the period. Finally, Choreo LLC raised its holdings in shares of Mesoblast by 15.1% in the fourth quarter. Choreo LLC now owns 12,225 shares of the company’s stock valued at $227,000 after acquiring an additional 1,600 shares in the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.